Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
{{output}}
Background: Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Av... ...
